Final Efficacy Outcomes of Atezolizumab with Chemoradiation for Unresectable NSCLC: The Phase II DETERRED Trial

Yufei Liu,Luyang Yao,Neda Kalhor,Brett W. Carter,Mehmet Altan,George Blumenschein,Lauren A. Byers,Frank Fossella,Don L. Gibbons,Jonathan M. Kurie,Charles Lu,Ferdinandos Skoulidis,Joe Y. Chang,Zhongxing Liao,Daniel R. Gomez,Michael O'Reilly,John V. Heymach,Anne S. Tsao,Steven H. Lin

Lung Cancer（2022）

引用 3|浏览9

暂无评分

摘要

•Stage 3 non-small cell lung cancer is treated with durvalumab after chemoradiation.•The DETERRED trial showed similar efficacy using a different immunotherapy agent.•Tumors with driver oncogene mutations may derive less benefit from this approach.•Tumors with low PD-L1 may derive less benefit from this approach.

查看译文

关键词

Non-small cell lung cancer,Atezolizumab,Immunotherapy,Radiation,Driver mutations,Targeted therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要